Iconovo AB (publ) (STO:ICO)
Sweden
· Delayed Price · Currency is SEK 1.200
+0.030 (2.56%)
At close: Mar 6, 2026
Iconovo AB Company Description
Iconovo AB (publ) develops inhaled medicinal products in Sweden.
The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use.
It serves generic companies. The company has a collaboration agreement with Lonza to develop spray-dried formulations of an intranasal biologic drug; and agreement with Kiox Pharma to develop an inhalable treatment for interstitial lung disease.
Iconovo AB (publ) was founded in 2013 and is headquartered in Lund, Sweden.
Iconovo AB (publ)
| Country | Sweden |
| Founded | 2013 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Anders Mansson |
Contact Details
Address: Ideongatan 3 A-B Lund, 223 70 Sweden | |
| Phone | 46 4 62 75 67 77 |
| Website | iconovo.se |
Stock Details
| Ticker Symbol | ICO |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0010868943 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Anders Mansson | Chief Executive Officer |
| Dr. Orest Lastow | Co-Founder, Senior Scientific Advisor and Director |
| Henrik Damkjaer Simonsen M.Sc. | Chief Financial Officer |
| Dr. Mikael Arinder | Head of Science and Technology |
| Lotta Askerlund | HR Manager |
| Carl Forslund | Head of Industrial Design |
| Vesna Åkerberg | Head of Novel and Reformulation Development |
| Maria Ekblad | Head of Generics Development |
| Madeleine Hiller | Business Controller |